Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TCF4 | P15884 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL439090 | 0.94 | CYP2C9 (0.45) | CYP2C9ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL439133 | 0.91 | ALDH1A1 (0.46) | CYP2C9ALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL469020 | 0.89 | ALDH1A1 (0.44) | CYP2C9ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL12723337 | 0.89 | MAPT (0.42) | CYP2C9ALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL437779 | 0.88 | ALDH1A1 (0.43) | CYP2C9ALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL439172 | 0.88 | CYP2C9 (0.41) | CYP2C9ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL10106985 | 0.86 | MAPT (0.44) | CYP2C9ALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL13656825 | 0.86 | CYP2C9 (0.40) | CYP2C9ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL437775 | 0.85 | ALDH1A1 (0.45) | CYP2C9ALDH1A1KMT2AMEN1CYP3A4 | |
| SCHEMBL439736 | 0.85 | ALDH1A1 (0.45) | ALDH1A1KMT2AMEN1CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120061325-A1 | CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS | THE CURATORS OF THE UNIVERSITY OF MISSOURI | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120061325-A1 | CHELATING COMPOUNDS AND IMMOBILIZED TETHERED CHELATORS | BTD, TTPA, SLC39A7 | CYP2C9 4522/4885ALDH1A1 3904/4885KMT2A 409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.